Jaguar Health Targets Mid-2027 MVID Filing After More Than $10 Million in Debt Reduction
Participants in the pivotal pediatric MVID trial have entered extension dosing. Jaguar also plans to seek breakthrough therapy designation in 2027.

Jaguar Health is targeting a mid-2027 new drug application submission for crofelemer to treat pediatric MVID after completing pivotal-trial enrollment, with participants now in extension dosing.
Jaguar plans to seek breakthrough therapy designation in 2027. The designation could potentially enable a four-month Food and Drug Administration review.
The company reduced its outstanding debt by more than $10 million in Q3 2026. The update adds clinical and debt milestones to Jaguar’s quarterly results, which included $2.343 million in revenue and a $9.23 net loss per share.
Jaguar’s prescription product net revenue was about $500,000 in Q3 2026, compared with about $1.2 million in Q2 2026. U.S. revenue from Mytesi and Canalevia-CA1 has been directed to Future Pak since Jan. 12, 2026. Jaguar supplies the products under cost-plus terms.
The company’s next stated milestone is its targeted mid-2027 NDA submission.